Drugs / NENDRATAREOTIDE UZATANSINE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02936323 | Dec 2016 → Jul 2020 | small cell lung carcinoma | Tarveda Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NENDRATAREOTIDE UZATANSINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650335 ↗ |
| Known as | PEN-221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02936323 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL4650335 ↗ |
| Route | Intravenous | “PEN-221 administered IV over 1 hour” NCT02936323 ↗ |